STOCK TITAN

Evotec SE - EVOTF STOCK NEWS

Welcome to our dedicated news page for Evotec SE (Ticker: EVOTF), a resource for investors and traders seeking the latest updates and insights on Evotec SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evotec SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evotec SE's position in the market.

Rhea-AI Summary
Evotec SE (EVT) announced a scientific achievement in its strategic partnership with Bristol Myers Squibb, resulting in a US$ 25 million payment to further research the joint neuroscience pipeline. The collaboration aims to develop disease-modifying treatments for neurodegenerative diseases, with a successful Phase I study leading to a Phase II study for BMS-986419 scheduled to commence in 2024. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, expressed confidence in delivering new therapeutic options for patients affected by neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
partnership
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
covid-19
Evotec SE

OTC:EVOTF

EVOTF Rankings

EVOTF Stock Data

2.62B
145.80M
9.21%
53.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Hamburg

About EVOTF

evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. the company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, inflammation and infectious diseases. by leveraging this expertise, evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure. evotec has long-term discovery alliances with partners including bayer, boehringer ingelheim, chdi, genentech, janssen pharmaceu